Advocates for Opioid Recovery
Every 19 min. a person dies from the cycle of opioid addiction.
Rewrite the Prescription
on opioid treatmentJoin Our Thunderclap!
Watch the Video
Opioid overdose is now the #1 cause of accidental death in America
in 2014 from drug overdose
Traditional treatment leads to relapse 85% of the time, creating a vicious rehab/addiction cycle.
Nobody wants to wake up in the morning looking to alienate their family and friends. Nobody chooses to be separated from their social circles. Nobody makes the conscious decision to put their careers in jeopardy. But that’s what addiction to opioids does. Addiction is a disease—and it’s one that I have lived with. I work every day on my recovery, and my hope is that my experience can be a beacon of hope for others seeking a life free from addiction.
Patrick J. Kennedy
New Science = New Hope
Medication is the most effective path to long term recovery
More people completed a six-month treatment program when they used recovery medication
Recovery medication improves outcomes
Decreases fatal overdoses
One study showed that increasing the availability of recovery medication led to 50% fewer fatal overdoses.
Decreases illicit opioid use
40% of patients being treated with medication did not relapse, compared to 28% without medication.
Reduces repeat criminal activity
Decreased the likelihood of drug relapse, overdose and recidivism among former inmates and increased their likelihood of remaining in long-term drug treatment.
Improves birth outcomes
Improves birth outcomes among pregnant women who have substance use disorders compared with no recovery medication treatment.
Thousands of people are dying waiting for access to opioid addiction treatment.
Nearly 80 percent of people with opioid addiction—over 1.9 million people—do not receive treatment.
Individuals who are unable to access appropriate treatment for opioid use disorders are at substantial risk for substance abuse, criminal activity, infectious disease including HIV and hepatitis, overdose, and premature death.
Break Down the Barriers
Expand treatment capacity
Government regulations limit the number of patients a doctor can treat with certain opioid recovery medications to 275 and 100 for nurse practitioners and physician assistants. No other disease has those restrictions. The government should immediately eliminate this arbitrary and discriminatory cap.
- Raise the cap: The federal government must eliminate, or at minimum raise, the arbitrary 275 patient treatment cap per eligible provider to 500.
- Allow physician assistants and nurse practitioners to prescribe recovery medications at the same rates as physicians. Currently, PAs and NPs are held to the old arbitrary caps of treating 30 patients for the first year, and 100 patients thereafter.
Improve insurance coverage
Insurance plans and Medicaid should eliminate “fail first” programs or lifetime medication limits for opioid recovery medication.
Veterans are twice as likely to die from a drug overdose. Special focus should be given to ensure open access to recovery medication treatment for America's veterans.
Encourage treatment through drug courts and prisons
Local and state policies exist that prevent convicted criminals from using recovery medication. Prohibitions must stop and treatment should be encouraged.
If you know of a person affected by opioid addiction, tell them about treatment with medication and share this physician locator tool.
Change your mind
Some people have been resistant to using a medication to treat a medication-based addiction and believe that total abstinence is the only legitimate path forward. The evidence does not support this belief.
It’s time we rewrite the prescription for treating opioid addiction.
Follow the science and do your part to encourage the use of recovery medication.
1. Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report (MMWR). (2016). Increases in Drug and Opioid Overdose Deaths — United States, 2000-2014. Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6450a3.htm?s_cid=mm6450a3_w
2. Ling W, Casadonte P, Bigelow G, et al.: Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA 304:1576 1583, 2010 CrossRef, Medline)
3. Schwartz RP, Gryczynski J, O'Grady KE, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. Am J Public Health 2013;103:917-922
4. Nunn, Amy et al. “Methadone and Buprenorphine Prescribing and Referral Practices in US Prison Systems: Results from a Nationwide Survey.” Drug and alcohol dependence 105.1-2 (2009): 83–88. PMC. Web. 17 June 2016.
5. Thomas, Cindy Parks, Catherine Anne Fullerton, Meelee Kim, Leslie Montejano, D. Russell Lyman, Richard H. Dougherty, Allen S. Daniels, Sushmita Shoma Ghose, and Miriam E. Delphin-Rittmon. "Medication-Assisted Treatment With Buprenorphine: Assessing the Evidence." PS Psychiatric Services 65.2 (2014): 158-70
6. CL Arfken, CE Johanson, S diMenza et.al., “Expanding treatment capacity for opioid dependence with buprenorphine: National surveys of physicians.” Journal of Substance Abuse Treatment, September 2010.
7. “Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health,” Substance Abuse and Mental Health Services 7dministration, September 2015
8. Sigmon, Stacey C. “Access to Treatment for Opioid Dependence in Rural America: Challenges and Future Directions” University of Vermont, February 5, 2014.
9. Bohnert AS, Ilgen MA, Galea S, et al. (2011) Accidental poisoning mortality among patients in the Department of Veterans Affairs Health System. Med Care. 2011 Apr;49(4):393-6. Available at https://www.ncbi.nlm.nih.gov/pubmed/21407033